KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) EBITDA (2016 - 2025)

LifeMD's EBITDA history spans 14 years, with the latest figure at -$6.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 4.26% year-over-year to -$6.2 million; the TTM value through Dec 2025 reached -$6.5 million, up 71.09%, while the annual FY2025 figure was -$7.7 million, 62.41% up from the prior year.
  • EBITDA reached -$6.2 million in Q4 2025 per LFMD's latest filing, down from -$2.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.2 million in Q1 2025 to a low of -$16.1 million in Q2 2021.
  • Average EBITDA over 5 years is -$7.1 million, with a median of -$6.2 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 584.76% in 2021, then skyrocketed 134.94% in 2025.
  • A 5-year view of EBITDA shows it stood at -$13.7 million in 2021, then rose by 24.1% to -$10.4 million in 2022, then surged by 79.06% to -$2.2 million in 2023, then crashed by 174.87% to -$6.0 million in 2024, then dropped by 4.26% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for LFMD's EBITDA are -$6.2 million (Q4 2025), -$2.0 million (Q3 2025), and -$451562.0 (Q2 2025).